 "Claris Lifesciences gains on successfully undergoing USFDA (PV) audit")
Claris Lifesciences rose as much as 11.9% to Rs 366 has after the company received ‘no observations’ from USFDA post Pharmacovigilance audit.
“Claris Lifesciences Limited (CLL) along with its wholly owned subsidiary Claris Injectables Limited (CIL) announced today that it underwent a successful USFDA Pharmacovigilance (PV) audit from Monday 29th May to Wednesday 31st May with No Observation (i483s). The announcement was made during market hours today, 31 May 2017,” the company said in a statement.
At 11:43 am, the scrip pared some gains and was trading 5% higher at Rs 343 as against the 0.07% rise in S&P BSE Sensex. For the month of May, the company has underperformed the market, sliding 7.5% compared with 4.1% gain in Sensex.
On the BSE, 2.24 lakh shares were traded in the counter so far. The stock had hit a high and low of Rs 366 and Rs 327.90 so far during the day. The stock had last hit a 52-week high of Rs 430.10 on 16 December 2016.
“Claris Lifesciences Limited (CLL) along with its wholly owned subsidiary Claris Injectables Limited (CIL) announced today that it underwent a successful USFDA Pharmacovigilance (PV) audit from Monday 29th May to Wednesday 31st May with No Observation (i483s). The announcement was made during market hours today, 31 May 2017,” the company said in a statement.
At 11:43 am, the scrip pared some gains and was trading 5% higher at Rs 343 as against the 0.07% rise in S&P BSE Sensex. For the month of May, the company has underperformed the market, sliding 7.5% compared with 4.1% gain in Sensex.
On the BSE, 2.24 lakh shares were traded in the counter so far. The stock had hit a high and low of Rs 366 and Rs 327.90 so far during the day. The stock had last hit a 52-week high of Rs 430.10 on 16 December 2016.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%